Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Humacyte (HUMA) has issued an update.
Humacyte, Inc. has launched an underwritten public offering of 13.4 million shares at $3.00 per share, with an option for underwriters to purchase an additional 2.01 million shares. The anticipated net proceeds are roughly $37.4 million or $43.1 million if the option is fully exercised. This offering, expected to close by March 5, 2024, is part of a previously declared effective shelf registration statement. The company’s press releases regarding the offering’s commencement and pricing were reported but are not considered filed under securities law.
For a thorough assessment of HUMA stock, go to TipRanks’ Stock Analysis page.